GLYC Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 16:59):

Stats
Šios dienos apimtis	121 098
Vidutinė apimtis	502 619
Rinkos kapitalizacija	109.89M
EPS	$0 ( 2024-05-01 )
Kita pelno data	( $-0.150 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.94
ATR14	$0.0120 (0.70%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Koenig Scott	Buy	40 000	Stock Option (right to buy)
2024-05-01	Goldberg Mark Alan	Buy	40 000	Stock Option (right to buy)
2024-05-01	Pearson Timothy R	Buy	40 000	Stock Option (right to buy)
2024-05-01	King Rachel K.	Buy	40 000	Stock Option (right to buy)
2024-05-01	Andrews Patricia S	Buy	40 000	Stock Option (right to buy)

INSIDER POWER
29.87
Last 98 transactions
Buy: 6 982 849 \| Sell: 4 750 194

Tūris Koreliacija

Ilgas: -0.08 (neutral)

Trumpas: -0.16 (neutral)

Signal:(50.267) Neutral

GlycoMimetics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

GlycoMimetics Inc Koreliacija - Valiuta/Žaliavos

-0.20
( neutral )

-0.16
( neutral )

0.00
( neutral )

-0.77
( moderate negative )

0.67
( moderate )

GlycoMimetics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$10 000.00
Bruto pelnas:	$-143 301 (-1 433.01 %)
EPS:	$-0.580

FY	2023
Pajamos:	$10 000.00
Bruto pelnas:	$-143 301 (-1 433.01 %)
EPS:	$-0.580

FY	2022
Pajamos:	$74 925.00
Bruto pelnas:	$-957 231 (-1 277.59 %)
EPS:	$-1.780

FY	2021
Pajamos:	$1 160.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.230

Financial Reports:

No articles found.

GlycoMimetics Inc

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.